

Supplementary Online Content

Flores-Guerrero JL, Minović I, Groothof D, et al. Association of plasma concentration of vitamin B₁₂ with all-cause mortality in the general population in the Netherlands. *JAMA Netw Open*. 2020;3(1):e1919274. doi:10.1001/jamanetworkopen.2019.19274

eTable 1. Multivariable Linear Regression Analyses With Plasma Concentration of Vitamin B₁₂ as the Dependent Variable

eTable 2. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With History of Cardiovascular Disease

eTable 3. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With History of Cancer

eTable 4. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With Low Plasma Concentrations Vitamin B₁₂

eTable 5. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With High Plasma Concentrations Homocysteine

eTable 6. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality in All Individuals With Available Information

eTable 7. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With Mild to Moderated Loss of Kidney Function

eTable 8. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality in a Design-Based Analysis

eTable 9. All-Cause Mortality Relative Risks for Each Stratum of Smoking Behavior

eTable 10. All-Cause Mortality Relative Risks for Each Stratum of Alcohol Consumption Behavior

eTable 11. All-Cause Mortality Relative Risks for Each Stratum of Age

eTable 12. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of Cancer Mortality

eTable 13. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of Cardiovascular Mortality

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Multivariable Linear Regression Analyses With Plasma Concentration of Vitamin B₁₂ as the Dependent Variable

Variables	b	b (95% CI)	β	β (95% CI)	P-value
Sex	0.92	[-9.97, 11.81]	0.00	[-0.04, 0.05]	0.86
Age	0.14	[-0.35, 0.63]	0.01	[-0.04, 0.06]	0.58
Ethnicity	-10.49	[-29.20, 8.22]	-0.02	[-0.05, 0.01]	0.27
Education (high)	0.74	[-7.89, 9.38]	0.00	[-0.03, 0.04]	0.86
BMI, kg/m ²	-0.58	[-1.59, 0.43]	-0.02	[-0.06, 0.02]	0.26
DBP, mm Hg	-0.16	[-0.48, 0.17]	-0.03	[-0.08, 0.03]	0.35
SBP, mm Hg	0.62	[-0.02, 1.25]	0.05	[0.00, 0.10]	0.05
Parental history of CKD	-7.70	[-55.20, 39.80]	-0.01	[-0.04, 0.03]	0.75
Parental history of T2D	-1.92	[-11.97, 8.14]	-0.01	[-0.04, 0.03]	0.70
T2D	5.47	[-16.78, 27.71]	0.01	[-0.03, 0.05]	0.62
Cancer history	2.40	[-15.54, 20.34]	0.00	[-0.03, 0.04]	0.79
CVD history	1.48	[-16.45, 19.40]	0.00	[-0.03, 0.04]	0.87
Smoking	-0.59	[-3.98, 2.80]	-0.01	[-0.04, 0.03]	0.73
Alcohol intake	-3.93	[-9.60, 1.74]	-0.02	[-0.06, 0.01]	0.17
Antihypertensive drugs	8.63	[-2.11, 19.37]	0.03	[-0.01, 0.07]	0.11
Lipid-lowering drugs	15.42	[0.60, 30.25]	0.04	[0.01, 0.07]	0.04*
Ferritin, (μ g/L)	0.05	[0.01, 0.08]	0.05	[0.02, 0.09]	0.005**
Transferrin, (g/L)	-12.62	[-22.66, -2.58]	-0.04	[-0.08, -0.01]	0.01*
Hemoglobin, mmol/L	23.95	[5.85, 42.04]	0.15	[0.04, 0.27]	0.009**
Hematocrit, (%)	-333.02	[-695.34, 29.30]	-0.10	[-0.21, 0.01]	0.07
MCV, (fL)	-2.18	[-3.11, -1.25]	-0.09	[-0.12, -0.05]	<0.001***
Homocysteine, (μ mol/L)	-9.02	[-10.00, -8.04]	-0.34	[-0.38, -0.30]	<0.001***
TC, mmol/L	2.60	[-1.60, 6.79]	0.02	[-0.01, 0.06]	0.22
HDL-C, mmol/L	32.88	[17.58, 48.18]	0.09	[0.05, 0.13]	<0.001***
TG, mmol/L	-5.60	[-10.73, -0.47]	-0.04	[-0.08, -0.00]	0.03*
Glucose, mmol/L	3.04	[-1.69, 7.76]	0.03	[-0.02, 0.07]	0.20
CRP, mg/L	0.26	[-0.44, 0.95]	0.01	[-0.02, 0.05]	0.47
eGFR, mL/min/1.73m ²	-0.78	[-1.11, -0.46]	-0.11	[-0.16, -0.07]	<0.001***
UAE, mg/24h	0.01	[-0.01, 0.04]	0.02	[-0.01, 0.05]	0.28
ALT, (U/L)	0.66	[0.23, 1.09]	0.08	[0.03, 0.13]	0.002**
AST, (U/L)	0.74	[0.05, 1.42]	0.05	[0.01, 0.10]	0.03*
ALP, (U/L)	0.18	[-0.03, 0.38]	0.03	[0.00, 0.07]	0.08
GGT, (U/L)	0.20	[0.06, 0.33]	0.06	[0.02, 0.10]	0.005**

Standardized (β) and unstandardized (b) regression coefficients are shown. Significance codes: ‘***’: < 0.001; ‘**’: < 0.01; ‘*’: < 0.05.

eTable 2. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With History of Cardiovascular Disease

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5202		1286	2607		1309	
Events, <i>n</i>	167		29	83		55	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.32 [1.13;1.53]	<0.001	(ref)	1.40 [0.91;2.13]	0.12	1.84 [1.17;2.88]	0.007
Model 1	1.32 [1.13;1.55]	<0.001	(ref)	1.37 [0.90;2.09]	0.14	1.83 [1.16;2.87]	0.008
Model 2	1.35 [1.14;1.59]	<0.001	(ref)	1.29 [0.83;2.00]	0.25	1.86 [1.15;2.98]	0.01
Model 3	1.42 [1.20;1.69]	<0.001	(ref)	1.40 [0.88;2.22]	0.15	2.05 [1.24;3.38]	0.005
Model 4	1.40 [1.17;1.67]	<0.001	(ref)	1.38 [0.86;2.22]	0.18	1.93 [1.16;3.23]	0.01
Model 5	1.40 [1.17;1.67]	<0.001	(ref)	1.36 [0.85;2.18]	0.20	1.90 [1.13;3.18]	0.01
Model 6	1.42 [1.18;1.71]	<0.001	(ref)	1.43 [0.87;2.37]	0.16	2.13 [1.23;3.69]	0.006
Model 7	1.41 [1.17;1.71]	<0.001	(ref)	1.44 [0.87;2.37]	0.15	2.12 [1.22;3.68]	0.007

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine

Model 3: Model 2 + ferritin + hemoglobin + MCV

Model 4: Model 3 + TC / HDL-C ratio + glucose

Model 5: Model 4 + cancer history

Model 6: Model 5 + eGFR + UAE

Model 7: Model 6 + ALT + AST + ALP + GGT

eTable 3. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With History of Cancer

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5308		1319	2655		1334	
Events, <i>n</i>	203		36	101		66	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.21 [1.06;1.39]	0.006	(ref)	1.38 [0.94;2.02]	0.09	1.79 [1.19;2.69]	0.004
Model 1	1.21 [1.05;1.39]	0.008	(ref)	1.37 [0.93;2.00]	0.10	1.75 [1.17;2.63]	0.007
Model 2	1.25 [1.07;1.44]	0.003	(ref)	1.35 [0.91;1.99]	0.13	1.91 [1.25;2.92]	0.002
Model 3	1.25 [1.07;1.47]	0.005	(ref)	1.42 [0.93;2.15]	0.10	1.84 [1.17;2.92]	0.008
Model 4	1.25 [1.06;1.47]	0.007	(ref)	1.42 [0.93;2.17]	0.10	1.81 [1.13;2.87]	0.01
Model 5	1.23 [1.05;1.45]	0.01	(ref)	1.40 [0.92;2.13]	0.12	1.75 [1.10;2.80]	0.01
Model 6	1.23 [1.04;1.46]	0.01	(ref)	1.46 [0.93;2.27]	0.09	1.90 [1.16;3.11]	0.01
Model 7	1.23 [1.04;1.46]	0.01	(ref)	1.45 [0.93;2.27]	0.09	1.91 [1.16;3.13]	0.01

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine

Model 3: Model 2 + ferritin + hemoglobin + MCV

Model 4: Model 3 + TC / HDL-C ratio + glucose

Model 5: Model 4 + CVD history

Model 6: Model 5 + eGFR + UAE

Model 7: Model 6 + ALT + AST + ALP + GGT

eTable 4. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With Low Plasma Concentrations Vitamin B₁₂

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5376		1344	2685		1347	
Events, <i>n</i>	217		36	111		70	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.27 [1.12;1.45]	<0.001	(ref)	1.52 [1.04;2.21]	0.02	1.91 [1.28;2.86]	0.001
Model 1	1.26 [1.11;1.44]	<0.001	(ref)	1.47 [1.01;2.14]	0.04	1.87 [1.25;2.80]	0.002
Model 2	1.29 [1.13;1.48]	<0.001	(ref)	1.48 [1.01;2.19]	0.04	2.00 [1.31;3.05]	0.001
Model 3	1.29 [1.12;1.50]	<0.001	(ref)	1.47 [0.98;2.21]	0.06	1.87 [1.19;2.93]	0.006
Model 4	1.28 [1.10;1.48]	0.001	(ref)	1.45 [0.96;2.17]	0.07	1.79 [1.14;2.81]	0.01
Model 5	1.26 [1.08;1.46]	0.002	(ref)	1.43 [0.96;2.15]	0.08	1.75 [1.11;2.76]	0.01
Model 6	1.28 [1.09;1.49]	0.002	(ref)	1.46 [0.95;2.26]	0.08	1.93 [1.19;3.12]	0.007
Model 7	1.28 [1.10;1.50]	0.001	(ref)	1.44 [0.93;2.22]	0.09	1.93 [1.19;3.13]	0.007

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine

Model 3: Model 2 + ferritin + hemoglobin + MCV

Model 4: Model 3 + TC / HDL-C ratio + glucose

Model 5: Model 4 + cancer history + CVD history

Model 6: Model 5 + eGFR + UAE

Model 7: Model 6 + ALT + AST + ALP + GGT

eTable 5. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With High Plasma Concentrations Homocysteine

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	4222		1055	2105		1062	
Events, <i>n</i>	120		17	63		40	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.38 [1.16;1.65]	<0.001	(ref)	1.85 [1.08;3.15]	0.02	2.33 [1.32;4.11]	0.003
Model 1	1.26 [1.05;1.51]	0.01	(ref)	1.47 [0.86;2.51]	0.15	1.79 [1.01;3.16]	0.04
Model 2	1.23 [1.03;1.48]	0.02	(ref)	1.43 [0.84;2.46]	0.18	1.73 [0.98;3.06]	0.06
Model 3	1.24 [1.02;1.51]	0.03	(ref)	1.22 [0.71;2.12]	0.47	1.57 [0.87;2.84]	0.13
Model 4	1.23 [1.00;1.50]	0.04	(ref)	1.23 [0.71;2.13]	0.45	1.52 [0.84;2.77]	0.17
Model 5	1.21 [0.99;1.48]	0.04	(ref)	1.24 [0.72;2.15]	0.44	1.46 [0.80;2.66]	0.21
Model 6	1.24 [1.01;1.53]	0.03	(ref)	1.25 [0.71;2.21]	0.43	1.58 [0.85;2.93]	0.14
Model 7	1.25 [1.02;1.54]	0.03	(ref)	1.27 [0.72;2.25]	0.41	1.64 [0.88;3.05]	0.12

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP

Model 3: Model 2 + ferritin + hemoglobin + MCV

Model 4: Model 3 + TC / HDL-C ratio + glucose

Model 5: Model 4 + cancer history + CVD history

Model 6: Model 5 + eGFR + UAE

Model 7: Model 6 + ALT + AST + ALP + GGT

eTable 6. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality in All Individuals With Available Information

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5629		1407	2813		1409	
Events, <i>n</i>	233		44	113		76	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.23 [1.08;1.40]	0.001	(ref)	1.27 [0.90;1.80]	0.17	1.71 [1.18;2.48]	0.004
Model 1	1.20 [1.06;1.36]	0.004	(ref)	1.26 [0.89;1.79]	0.18	1.67 [1.15;2.42]	0.006
Model 2	1.25 [1.09;1.42]	0.001	(ref)	1.28 [0.89;1.83]	0.18	1.81 [1.22;2.68]	0.002
Model 3	1.24 [1.08;1.43]	0.002	(ref)	1.33 [0.91;1.95]	0.14	1.75 [1.15;2.68]	0.009
Model 4	1.24 [1.07;1.43]	0.003	(ref)	1.32 [0.90;1.95]	0.15	1.71 [1.11;2.63]	0.01
Model 5	1.20 [1.04;1.39]	0.01	(ref)	1.32 [0.89;1.94]	0.16	1.64 [1.07;2.53]	0.02
Model 6	1.21 [1.04;1.41]	0.01	(ref)	1.35 [0.90;2.03]	0.14	1.79 [1.13;2.83]	0.01
Model 7	1.23 [1.05;1.44]	0.009	(ref)	1.32 [0.88;1.99]	0.18	1.80 [1.14;2.86]	0.01

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex.

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP

Model 3: Model 2 + ferritin + hemoglobin + MCV.

Model 4: Model 3 + TC/HDL-C ratio + glucose.

Model 5: Model 4 + cancer history + CVD history.

Model 6: Model 5 + eGFR + UAE.

Model 7: Model 6 + ALT + AST + ALP + GGT + B₁₂ supplementation

eTable 7. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality After Excluding Individuals With Mild to Moderate Loss of Kidney Function

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5342		1333	2665		1344	
Events, <i>n</i>	180		34	89		57	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.20 [1.04;1.39]	0.01	(ref)	1.30 [0.87;1.92]	0.20	1.64 [1.07;2.51]	0.02
Model 1	1.19 [1.03;1.38]	0.01	(ref)	1.30 [0.88;1.93]	0.19	1.63 [1.07;2.50]	0.02
Model 2	1.19 [1.01;1.39]	0.03	(ref)	1.23 [0.82;1.85]	0.32	1.63 [1.04;2.55]	0.03
Model 3	1.20 [1.02;1.43]	0.03	(ref)	1.24 [0.80;1.91]	0.33	1.62 [1.00;2.62]	0.04
Model 4	1.20 [1.01;1.43]	0.03	(ref)	1.22 [0.78;1.89]	0.38	1.58 [0.97;2.58]	0.06
Model 5	1.17 [0.99;1.40]	0.06	(ref)	1.21 [0.78;1.88]	0.39	1.52 [0.93;2.50]	0.09
Model 6	1.19 [0.99;1.43]	0.06	(ref)	1.26 [0.79;2.01]	0.33	1.70 [1.01;2.87]	0.04
Model 7	1.18 [0.98;1.42]	0.07	(ref)	1.28 [0.80;2.05]	0.29	1.70 [1.00;2.89]	0.04

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex.

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine.

Model 3: Model 2 + ferritin + hemoglobin + MCV.

Model 4: Model 3 + TC/HDL-C ratio + glucose.

Model 5: Model 4 + cancer history + CVD history.

Model 6: Model 5 + eGFR + UAE.

Model 7: Model 6 + ALT + AST + ALP + GGT.

eTable 8. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of All-Cause Mortality in a Design-Based Analysis

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5571		1390	2787		1394	
Events, <i>n</i>	226		41	112		73	
	HR (95 % CI)	P-Value		HR (95 % CI)	P-Value	HR (95 % CI)	P-Value
Crude Model	1.36 [1.17;1.57]	<0.001	(ref)	1.19 [0.80;1.77]	0.40	2.06 [1.37;3.10]	<0.001
Model 1	1.32 [1.14;1.53]	<0.001	(ref)	1.19 [0.80;1.78]	0.38	1.98 [1.31;2.98]	0.001
Model 2	1.38 [1.18;1.62]	<0.001	(ref)	1.20 [0.79;1.82]	0.38	2.21 [1.43;3.43]	<0.001
Model 3	1.38 [1.17;1.63]	<0.001	(ref)	1.23 [0.80;1.89]	0.35	2.13 [1.34;3.38]	0.001
Model 4	1.33 [1.12;1.57]	0.001	(ref)	1.16 [0.75;1.80]	0.49	1.90 [1.19;3.05]	0.007
Model 5	1.30 [1.10;1.54]	0.002	(ref)	1.15 [0.74;1.79]	0.52	1.84 [1.15;2.97]	0.01
Model 6	1.33 [1.12;1.58]	0.001	(ref)	1.17 [0.75;1.84]	0.48	2.00 [1.22;3.25]	0.005
Model 7	1.33 [1.12;1.59]	0.001	(ref)	1.16 [0.74;1.81]	0.52	2.01 [1.23;3.30]	0.005

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex.

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine

Model 3: Model 2 + ferritin + hemoglobin + MCV.

Model 4: Model 3 + TC/HDL-C ratio + glucose.

Model 5: Model 4 + cancer history + CVD history.

Model 6: Model 5 + eGFR + UAE.

Model 7: Model 6 + ALT + AST + ALP + GGT + B₁₂ supplementation

eTable 9. All-Cause Mortality Relative Risks for Each Stratum of Smoking Behavior

	All-cause mortality			Proportion of deaths (all-cause mortality) (%)
	Dead	Alive	Total	
<i>All participants^a</i>				
Q1 of Vitamin B ₁₂	41	1349	1390	2.9
Q2+Q3 of Vitamin B ₁₂	112	2675	2787	4.0
Q4 of Vitamin B ₁₂	73	1321	1394	5.2
<i>Participants who never smoked^b</i>				
Q1 of Vitamin B ₁₂	7	372	379	1.8
Q2+Q3 of Vitamin B ₁₂	13	765	778	1.7
Q4 of Vitamin B ₁₂	12	408	420	2.9
<i>Former smokers^c</i>				
Q1 of Vitamin B ₁₂	25	556	581	4.3
Q2+Q3 of Vitamin B ₁₂	61	1119	1180	5.2
Q4 of Vitamin B ₁₂	42	575	617	6.8
<i>Current smokers^d</i>				
Q1 of Vitamin B ₁₂	9	400	409	2.2
Q2+Q3 of Vitamin B ₁₂	37	759	796	4.6
Q4 of Vitamin B ₁₂	19	323	342	5.6

a. Crude Relative Risk=5.2%/2.9% = 1.8.

b. Stratum-specific Relative Risk =2.9%/1.8% = 1.6.

c. Stratum-specific Relative Risk =6.8%/4.3% = 1.6.

d. Stratum-specific Relative Risk =5.6%/2.2% = 2.5.

eTable 10. All-Cause Mortality Relative Risks for Each Stratum of Alcohol Consumption Behavior

	All-cause mortality			Proportion of deaths (all-cause mortality) (%)
	Dead	Alive	Total	
<i>All Participants^a</i>				
Q1 of Vitamin B ₁₂	41	1349	1390	2.9
Q2+Q3 of Vitamin B ₁₂	112	2675	2787	4.0
Q4 of Vitamin B ₁₂	73	1321	1394	5.2
<i>Participants with alcohol intake < 1 drinks/week^b</i>				
Q1 of Vitamin B ₁₂	15	337	352	4.5
Q2+Q3 of Vitamin B ₁₂	33	674	707	4.7
Q4 of Vitamin B ₁₂	20	345	365	5.5
<i>Participants with alcohol intake = 1-7 drinks/week^c</i>				
Q1 of Vitamin B ₁₂	20	650	670	3.0
Q2+Q3 of Vitamin B ₁₂	49	1316	1365	3.6
Q4 of Vitamin B ₁₂	28	590	618	4.5
<i>Participants with alcohol intake > 7 drinks/week^d</i>				
Q1 of Vitamin B ₁₂	15	337	352	4.3
Q2+Q3 of Vitamin B ₁₂	33	674	707	4.7
Q4 of Vitamin B ₁₂	20	345	365	5.5

a. Crude Relative Risk=5.2%/2.9% = 1.8.

b. Stratum-specific Relative Risk =5.5%/4.5% = 1.2.

c. Stratum-specific Relative Risk =4.5%/3.0% = 1.5.

d. Stratum-specific Relative Risk =5.5%/4.3% = 1.3.

eTable 11. All-Cause Mortality Relative Risks for Each Stratum of Age

	All-cause mortality			Proportion of deaths (all-cause mortality) (%)
	Dead	Alive	Total	
<i>All Participants^a</i>				
Q1 of Vitamin B ₁₂	41	1349	1390	2.9
Q2+Q3 of Vitamin B ₁₂	112	2675	2787	4.0
Q4 of Vitamin B ₁₂	73	1321	1394	5.2
<i>Participants <65 years old^b</i>				
Q1 of Vitamin B ₁₂	12	1089	1101	1.1
Q2+Q3 of Vitamin B ₁₂	31	2184	2215	1.4
Q4 of Vitamin B ₁₂	20	1061	1081	1.9
<i>Participants with ≥65 years old^c</i>				
Q1 of Vitamin B ₁₂	29	260	289	10.0
Q2+Q3 of Vitamin B ₁₂	81	491	572	14.2
Q4 of Vitamin B ₁₂	53	260	313	16.9

a. Crude Relative Risk=5.2%/2.9% = 1.8.

b. Stratum-specific Relative Risk =1.9%/1.1% = 1.7.

c. Stratum-specific Relative Risk =16.9%/10% = 1.7.

eTable 12. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of Cancer Mortality

	Vitamin B ₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, n	5571		1390	2787		1394	
Events, n	172		41	76		55	
	HR (95 % CI)	P Value		HR (95 % CI)	P Value	HR (95 % CI)	P Value
Crude Model	1.14 [0.98;1.33]	0.08	(ref)	0.94 [0.64;1.37]	0.73	1.36 [0.91;2.04]	0.13
Model 1	1.13 [0.97;1.31]	0.10	(ref)	0.92 [0.63;1.35]	0.67	1.33 [0.88;1.99]	0.17
Model 2	1.12 [0.96;1.32]	0.15	(ref)	0.86 [0.58;1.28]	0.45	1.32 [0.86;2.02]	0.20
Model 3	1.12 [0.94;1.33]	0.20	(ref)	0.88 [0.58;1.33]	0.53	1.26 [0.80;2.00]	0.31
Model 4	1.10 [0.92;1.31]	0.29	(ref)	0.86 [0.56;1.30]	0.47	1.18 [0.74;1.87]	0.49
Model 5	1.09 [0.91;1.30]	0.35	(ref)	0.83 [0.55;1.27]	0.39	1.17 [0.73;1.86]	0.51
Model 6	1.11 [0.92;1.33]	0.26	(ref)	0.87 [0.57;1.35]	0.54	1.22 [0.75;1.98]	0.43
Model 7	1.13 [0.93;1.36]	0.21	(ref)	0.88 [0.57;1.36]	0.55	1.28 [0.78;2.09]	0.32

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex.

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine.

Model 3: Model 2 + ferritin + hemoglobin + MCV.

Model 4: Model 3 + TC/HDL-C ratio + glucose.

Model 5: Model 4 + cancer history + CVD history.

Model 6: Model 5 + eGFR + UAE.

Model 7: Model 6 + ALT + AST + ALP + GGT.

eTable 13. Prospective Associations of Plasma Concentration of Vitamin B₁₂ With Risk of Cardiovascular Mortality

	Vitamin B₁₂ Per 1 SD Increment		Q1	Q2+Q3		Q4	
Participants, <i>n</i>	5571		1390	2787		1394	
Events, <i>n</i>	53		8	29		16	
	HR (95 % CI)	P Value		HR (95 % CI)	P Value	HR (95 % CI)	P Value
Crude Model	1.20 [0.91;1.57]	0.19	(ref)	1.79 [0.82;3.91]	0.14	1.97 [0.84;4.61]	0.11
Model 1	1.20 [0.92;1.58]	0.18	(ref)	1.81 [0.83;3.97]	0.13	1.99 [0.85;4.66]	0.11
Model 2	1.24 [0.93;1.66]	0.14	(ref)	2.20 [0.97;4.98]	0.05	2.07 [0.80;5.32]	0.13
Model 3	1.21 [0.90;1.64]	0.21	(ref)	2.15 [0.94;4.92]	0.07	1.91 [0.72;5.04]	0.19
Model 4	1.20 [0.88;1.62]	0.25	(ref)	2.26 [0.97;5.27]	0.05	1.79 [0.66;4.86]	0.25
Model 5	1.16 [0.85;1.59]	0.34	(ref)	2.31 [0.98;5.42]	0.05	1.62 [0.58;4.54]	0.35
Model 6	1.07 [0.76;1.51]	0.69	(ref)	1.88 [0.79;4.51]	0.15	1.37 [0.46;4.03]	0.56
Model 7	1.06 [0.75;1.51]	0.74	(ref)	1.79 [0.74;4.32]	0.19	1.33 [0.45;3.95]	0.60

Data are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). For HR of Vitamin B₁₂ per 1 SD increment, data was log_e transformed.

Model 1: Model adjusted for age and sex.

Model 2: Model 1 + ethnicity + BMI + T2D + Smoking status (never, past, current) + Alcohol consumption (<1, 1-7,>7 drinks/week) + Education (low, medium, high) + SBP + homocysteine.

Model 3: Model 2 + ferritin + hemoglobin + MCV.

Model 4: Model 3 + TC/HDL-C ratio + glucose.

Model 5: Model 4 + cancer history + CVD history.

Model 6: Model 5 + eGFR + UAE.

Model 7: Model 6 + ALT + AST + ALP + GGT.